Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
Tóm tắt
Aminoglycosides have a concentration-dependent therapeutic effect when peak serum concentration (Cmax) reaches eight to tenfold the minimal inhibitory concentration (MIC). With an amikacin MIC of 8 mg/L, the Cmax should be 64–80 mg/L. This objective is based on clinical breakpoints and not on measured MIC. This study aimed to assess the proportion of patients achieving the pharmacokinetic/pharmacodynamic (PK/PD) target Cmax/MIC ≥ 8 using the measured MIC in critically ill patients treated for documented Gram-negative bacilli (GNB) infections. Retrospective analysis from February 2016 to December 2017 of a prospective database conducted in 2 intensive care units (ICU). All patients with documented severe GNB infections treated with amikacin (single daily dose of 25 mg/kg of total body weight (TBW)) with both MIC and Cmax measurements at first day of treatment (D1) were included. Results are expressed in n (%) or median [min–max]. 93 patients with 98 GNB-documented infections were included. The median Cmax was 55.2 mg/L [12.2–165.7] and the median MIC was 2 mg/L [0.19–16]. Cmax/MIC ratio ≥ 8 was achieved in 87 patients (88.8%) while a Cmax ≥ 64 mg/L was achieved in only 38 patients (38.7%). Overall probability of PK/PD target attainment was 93%. No correlation was found between Cmax/MIC ratio and clinical outcome at D8 and D28. According to PK/PD parameters observed in our study, single daily dose of amikacin 25 mg/kg of TBW appears to be sufficient in most critically ill patients treated for severe GNB infections.
Tài liệu tham khảo
Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462–74.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77. https://doi.org/10.1007/s00134-017-4683-6.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–9.
EUCAST. Aminoglycosides: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf.n.d.
ANSM. Bon usage des aminosides administrés par voie injectable: gentamicine, tobramycine, netilmicine, amikacine – Mise au point 2011.
Gálvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38:146–51. https://doi.org/10.1016/j.ijantimicag.2011.03.022.
de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25?mg/kg total body weight regimen. Intensive Care Med. 2014;40:998–1005. https://doi.org/10.1007/s00134-014-3276-x.
Taccone F, Laterre P-F, Spapen H, Dugernier T, Delattre I, Layeux B, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14:R53. https://doi.org/10.1186/cc8945.
Décret n° 2016-1537 du 16 novembre 2016 relatif aux recherches impliquant la personne humaine. Disponible sur https://www.legifrance.gouv.fr/eli/decret/2016/1/16/AFSP1621392D/jo/texte Alias: https://www.legifrance.gouv.fr/eli/decret/2016/11/16/2016-1537/jo/texte.n.d.
CDC. CDC/NHSN Surveillance Definitions for Specific Types of Infections. Available of https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf.n.d.
Blaser J, König C, Fatio R, Follath F, Cometta A, Glauser M. Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. Ther Drug Monit. 1995;17:133–6. https://doi.org/10.1097/00007691-199504000-00005.
Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.
Boidin C, Jenck S, Bourguignon L, Torkmani S, Roussey-Jean A, Ledochowski S, et al. Determinants of amikacin first peak concentration in critically ill patients. Fundam Clin Pharmacol. 2018. https://doi.org/10.1111/fcp.12374.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509. https://doi.org/10.1016/S1473-3099(14)70036-2.
Allou N, Bouteau A, Allyn J, Snauwaert A, Valance D, Jabot J, et al. Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. Ann Intensive Care. 2016. https://doi.org/10.1186/s13613-016-0211-z.
Burdet C, Pajot O, Couffignal C, Armand-Lefèvre L, Foucrier A, Laouénan C, et al. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75–83. https://doi.org/10.1007/s00228-014-1766-y.
Pajot O, Burdet C, Couffignal C, Massias L, Armand-Lefevre L, Foucrier A, et al. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. J Antimicrob Chemother. 2015;70:1487–94. https://doi.org/10.1093/jac/dku569.
EUCAST. Antimicrobial wild type distributions of microorganisms. https://mic.eucast.org/Eucast2.n.d.
Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71:208–12. https://doi.org/10.1093/jac/dkv291.
De Winter S, Wauters J, Meersseman W, Verhaegen J, Van Wijngaerden E, Peetermans W, et al. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. Int J Antimicrob Agents. 2018;51:562–70. https://doi.org/10.1016/j.ijantimicag.2017.11.009.
Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–9.
Duszynska W, Taccone F, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojeńska A, Kübler A. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013;17:R165. https://doi.org/10.1186/cc12844.
Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003–12.